AbCellera Biologics Inc. Earnings Recaps
Q2 2026
Aug 7, 2026
AbCellera's stock rose 7.2% after announcing sizable upfront payments from its new T cell engager (TCE) collaborations with Vertex and Jazz Pharmaceuticals, which added over $110 million in near-term cash and significant potential downstream revenue.
Key takeaways
- Completed enrollment and initial dosing for the Phase II study of ABCL635 in menopause-related hot flashes, with data expected imminently.
- Advanced pipeline programs ABCL-688 and ABCL386 are expected to enter Phase I/II trials in 2027; ABCL575 Phase I dosing completed with readout due in Q4.
- Missed prior goal to move a program into IND-enabling activities in H1 but reported ongoing progress in discovery.
- Announced two new TCE collaborations: $28 million upfront from Vertex targeting autoimmune diseases, and $84 million upfront (with $56 million received) from Jazz, with potential total deal values exceeding $4 billion across five programs.
- Strong liquidity position with $565 million cash and equivalents plus $110 million of committed government funding to support strategic execution.
Q1 2026
May 13, 2026
Shares declined 5.7% as investors reacted negatively to cautious outlook signals embedded in the update, notably the absence of new guidance and limited visibility on upcoming catalysts despite the Phase I data release.
Key takeaways
- ABCL635 advanced to Phase II based on encouraging interim Phase I safety and pharmacokinetic data, with no serious adverse events or liver toxicity reported.
- The Phase I trial included 40 healthy volunteers across single ascending dose cohorts; multiple ascending dose data remain blinded and pending.
- Management emphasized upcoming key catalysts in 2026, including top line data for ABCL635 in Q3 and pipeline advancement activities, but provided no updated financial guidance.
- The stock’s down move likely reflects investor disappointment in lack of new forward-looking clarity and incremental nature of the disclosed data.
- No commentary on revenue or margin trends was given, underscoring limited near-term visibility on financial performance.